Stocktoria

Immuneering Corp IMRX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-07-30

Immuneering Corp statistics & valuation

Market cap$308.0M
P / B1.4×
Return on equity-25.6%
Return on capital-26.8%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
44.60% 44.60% 50.10% 202020212022202320242025
Operating margin (%)
-739.00% -1629.20% -16325.80% 202020212022202320242025
Return on equity (%)
-21.50% -46.00% -59.00% -147.50% -25.60% 202020212022202320242025
Shares outstanding
5.0M 13.6M 26.4M 28.4M 30.0M 44.0M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-44.30% -20.10% -41.30% -52.10% -115.80% -24.20% 202020212022202320242025
Free cash flow margin (%)
-634.80% -1486.20% -14148.40% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$3.44 -$2.46 -$1.91 -$1.88 -$2.04 -$1.27 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Gross margin———50.1%44.6%44.6%
Operating margin———-16325.8%-1629.2%-739.0%
Net margin———-15937.3%-1612.3%-737.2%
FCF margin———-14148.4%-1486.2%-634.8%
Return on assets-24.2%-115.8%-52.1%-41.3%-20.1%-44.3%
Return on equity-25.6%-147.5%-59.0%-46.0%-21.5%75.8%
Current ratio17.505.2811.3513.5027.0416.73

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.